高级检索
当前位置: 首页 > 详情页

CD44(+)/CD24(+)-Expressing Cervical Cancer Cells and Radioresistant Cervical Cancer Cells Exhibit Cancer Stem Cell Characteristics

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Hebei Med Univ, Hosp 4, Dept Obstet & Gynecol, Shijiazhuang, Hebei, Peoples R China [2]Hebei Med Univ, Hosp 4, Dept Gynecol Tumor, Shijiazhuang 050011, Hebei, Peoples R China
出处:
ISSN:

关键词: Radiosensitivity Cancer stem cells Invasion Migratory Epithelial-mesenchymal transition

摘要:
Background: Radiation therapy is a mainstay in the treatment of cervical cancer. However, most advanced and metastatic cervical cancers are resistant to radiation therapy because of the presence of cancer stem cells (CSCs). To date, no specific markers were found for cervical CSCs. Methods: The fraction of CD44(+)/CD24(+) cell subpopulation was detected with flow cytometry (FCM). The clonogenicity and radiosensitivity were detected using colony-formation and radiosensitivity assay. Matrigel-transwell invasion assay was used to compare the invading capacity. We compared the tumor formation capacity using Tumor Xenografts. The expressions of apoptosis related factor, epithelial-mesenchymal transition and stem cell markers were detected with real-time polymerase chain reaction and western blot analysis. Results: This study shows that radiation-resistant cervical cancer cells are rich in CD44(+)/CD24(+)-expressing cervical cancer cells. Moreover, these 2 cells exhibit the same CSC characteristics, such as increased expression of Bcl-2, survivin, and stem cell markers being more tumorigenic. These cells also showed phenotypic molecular changes that are consistent with epithelial-mesenchymal transition. Conclusion: Our data suggested that CD44(+)/CD24(+)-expressing cervical cancer cells may perform an important function in the radioresistance of cervical cancer. The therapy, which focuses on CD44(+)/CD24(+)-expressing cervical cancer cells, can increase the radiosensitivity of cervical cancer. (C) 2018 S. Karger AG, Basel

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2019]版:
大类 | 4 区 医学
小类 | 4 区 妇产科学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 妇产科学
JCR分区:
出版当年[2019]版:
Q4 OBSTETRICS & GYNECOLOGY
最新[2023]版:
Q2 OBSTETRICS & GYNECOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者机构: [1]Hebei Med Univ, Hosp 4, Dept Obstet & Gynecol, Shijiazhuang, Hebei, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [2]Hebei Med Univ, Hosp 4, Dept Gynecol Tumor, Shijiazhuang 050011, Hebei, Peoples R China [*1]Department of Gynecological Tumor Fourth Hospital of Hebei Medical University Shijiazhuang 050011 (China)
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:39770 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号